Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence. Efficacy and biomarker analysis of phase 2 (P2) and ...
CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results